

University of Vermont Cancer Center
Clinical Investigator-Initiated Therapeutic Trial Opportunity (CIITTO)
February 2024
****This opportunity is not current active****

Program: The University of Vermont Cancer Center (UVMCC) will provide support of 20% effort through September 30, 2025 for up to one clinician to facilitate productivity and career development as a clinician investigator.

Rationale: UVMCC seeks to promote the development of investigator-initiated cancer-focused therapeutic clinical trials in order to provide the best opportunities for patients with cancer. Academic development and assistance of clinician investigators supports this goal¹.

Eligibility: Faculty level (assistant, associate or full professor) UVM Cancer Center members with UVM Medical Center medical staff privileges are eligible to apply.

Support: Successful candidates will be awarded funds to support 20% of faculty effort through September 30, 2025 to engage in cancer-focused scholarly activity. Awardees will also receive \$20,000 to support regulatory, data management and clinical research coordination through the UVMCC Clinical Trials Office.

Start date for this award can be between 4/1/24 and 7/1/24, depending on Departmental considerations. The requested start date should be indicated on the application form.

Deliverables: Successful candidates will be expected to develop and activate a minimum of two (2) investigator-initiated therapeutic clinical trial during the period of support, support enrollment to these trials, and explore collaborations with laboratory or population-based investigators for additional translational, implementation or dissemination research projects which may lead to future extramural funding applications. A progress report is due at the completion of the funding period.

Timelines:

Request for Applications (RFA) announcement: March 1, 2024

Proposal due date: March 25, 2024, 5:00pm

Notification of awards: March 29, 2024

Start date of award: Between April 1, 2024 and July 1, 2024

Submission guidelines:

Applications should be submitted to Ed North, Grants Manager, UVMCC, as a single electronic PDF document: Edward.north@med.uvm.edu

Content should include the following:

- All materials should be completed in Arial font, 11 point, with page margins of 1 inch top/bottom/sides
 - File should be titled as: CIITTO_LastName_FirstName_Date
- Proposal for a 2 investigator-initiated therapeutic trials – 2 pages

- Description of two proposed trials
 - Indicate how the trials are cancer focused and therapeutic
- Career development plan and future goals – ½ page
 - Describe how the award will facilitate the goals
- NIH style biosketch, with relevant publications and other support (maximum 5 pages)
 - Contact Ed North for assistance with formatting if required
- Signed approval form by Department Chair (and Division Chief if applicable)
 - The Department Chair/Division Chief must certify that the candidate will be afforded release time of no less than 20% to execute the goals and responsibilities under this award.

Proposals will be evaluated by a committee.

¹ **Holcombe RF**, Verschraegen C, Chapman AE, Gaffney D, Goldberg RM, Mesa RA, Milhem M, Mims MP, Mitchell EP, Mulkerin D, Vijayakumar S. Status of the clinician investigator in America: An essential health care provider driving advances in cancer care. Journal NCCN, 2021;19:122-125.

Please contact Dr. Holcombe for any questions, concerns, or feedback at:

randall.holcombe@med.uvm.edu

University of Vermont Cancer Center
Clinical Investigator-Initiated Therapeutic Trial Opportunity
February 2024

DEPARTMENTAL/DIVISIONAL APPROVAL FORM

Chair Name: _____

Chair Department: _____

Chair Email: _____

Division Chief Name: _____

Division: _____

Division Chief Email: _____

Applicant Name: _____

I am aware that the above named applicant has applied for support through the University of Vermont Cancer Center Clinical Investigator Initiated Therapeutic Trial Opportunity award. With my signature below I am providing authorization for this application and confirm that the applicant, if awarded, will be provided with 0.20 FTE to commit to the execution of the goals and objectives of this initiative, throughout its duration.

Chair Signature_____
Date_____
Chief Signature (if applicable)_____
Date

Signed form to be included with application materials.